Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | RET |
Variant | C609R |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | RET C609R lies within the extracellular domain of the Ret protein (UniProt.org). C609R reduces cell surface Ret expression, but also results in increased Ret and Shc phosphorylation, activation of transcription in reporter assays, and is transforming in cell culture (PMID: 9879991), therefore, is predicted to lead to a gain of Ret protein function. |
Associated Drug Resistance | |
Category Variants Paths |
RET mutant RET act mut RET C609R RET mutant RET C609X RET C609R |
Transcript | NM_020975.6 |
gDNA | chr10:g.43113621T>C |
cDNA | c.1825T>C |
Protein | p.C609R |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_020630.5 | chr10:g.43113621T>C | c.1825T>C | p.C609R | RefSeq | GRCh38/hg38 |
NM_001406744.1 | chr10:g.43113621T>C | c.1825T>C | p.C609R | RefSeq | GRCh38/hg38 |
NM_001406763.1 | chr10:g.43113621T>C | c.1825T>C | p.C609R | RefSeq | GRCh38/hg38 |
NM_001406759.1 | chr10:g.43113621T>C | c.1825T>C | p.C609R | RefSeq | GRCh38/hg38 |
NM_020630.7 | chr10:g.43113621T>C | c.1825T>C | p.C609R | RefSeq | GRCh38/hg38 |
NM_001406760.1 | chr10:g.43113621T>C | c.1825T>C | p.C609R | RefSeq | GRCh38/hg38 |
NM_020975.6 | chr10:g.43113621T>C | c.1825T>C | p.C609R | RefSeq | GRCh38/hg38 |
NM_020975.5 | chr10:g.43113621T>C | c.1825T>C | p.C609R | RefSeq | GRCh38/hg38 |
NM_001406765.1 | chr10:g.43113621T>C | c.1825T>C | p.C609R | RefSeq | GRCh38/hg38 |
NM_001406743.1 | chr10:g.43113621T>C | c.1825T>C | p.C609R | RefSeq | GRCh38/hg38 |
NM_020975 | chr10:g.43113621T>C | c.1825T>C | p.C609R | RefSeq | GRCh38/hg38 |
NM_020630 | chr10:g.43113621T>C | c.1825T>C | p.C609R | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|